VONTROL
LOE ApproachingNDAORALTABLET
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VONTROL is an oral small-molecule tablet approved by GSK in 1967 with an unknown mechanism of action and indication profile. The drug's specific therapeutic target and patient population cannot be determined from available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting commercial team and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job postings are linked to VONTROL, reflecting its late-stage lifecycle status. Career opportunities on this product are limited to defending market share and managing the transition to generic competition, with emphasis on compliance and cost optimization.
Brand ManagerField Sales Representative
Worked on VONTROL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.